首页 | 官方网站   微博 | 高级检索  
     

补血强肾方联合西药治疗慢性再生障碍性贫血患者的临床效果及对红细胞、白细胞介素的影响
引用本文:袁志军,刘爱林,刘玲玲. 补血强肾方联合西药治疗慢性再生障碍性贫血患者的临床效果及对红细胞、白细胞介素的影响[J]. 世界中医药, 2018, 0(11)
作者姓名:袁志军  刘爱林  刘玲玲
作者单位:1 武汉科技大学附属孝感医院,孝感,432000; 2 中山大学第一附属医院,广州,510080
基金项目:广东省自然科学基金项目(2014A030310292)
摘    要:目的:研究自拟补血强肾方联合西药治疗慢性再生障碍性贫血患者的临床效果及对患者的红细胞及白细胞介素的影响。方法:选取2014年6月至2015年12月间收治的慢性再生障碍性贫血患者46例作为研究对象,将患者随机均分为对照组与观察组,每组23例,对照组采取单纯西药治疗,观察组在对照组的基础上联合自拟补血强肾方治疗,治疗2个疗程后评估并比较2组疗效,观察治疗前后2组红细胞计数、网织红细胞、血红蛋白水平、骨髓增生,血清白细胞介素表达。结果:观察组临床治愈率为82. 61%,总有效率为95. 65%;对照组临床治愈率为56. 52%,总有效率为78. 26%;观察组临床疗效优于对照组,差异有统计学意义(P 0. 05)。与治疗前比较,治疗后2组RBC、RET、Hb均有所改善,差异有统计学意义(P 0. 05);治疗后观察组RBC、RET、Hb均优于对照组,差异有统计学意义(P 0. 05)。与治疗前比较,治疗后2组患者血清IL-17、IL-6、IL-23均有所下降,差异有统计学意义(P 0. 05);治疗后观察组IL-17、IL-6、IL-23均明显低于对照组,差异有统计学意义(P 0. 05)。治疗后观察组患者骨髓增生显著优于对照组,差异有统计学意义(P 0. 05)。RBC、Hb与临床疗效间呈高度负相关(P 0. 05),IL-23、IL-17、IL-6与临床疗效间正相关(P 0. 05)。结论:补血强肾方联合西药治疗慢性再生障碍性贫血疗效确切,能够有效改善红细胞及白细胞介素的表达。

关 键 词:慢性再生障碍性贫血;红细胞;白细胞介素-17;白细胞介素-6;白细胞介素-23;骨髓增生度;血红蛋白;中西医联合治疗
收稿时间:2017-09-06

Effect of Buxue Qiangshen Fang Combined with Western Medicine on Chronic Aplastic Anemia and Observation Study on Erythrocyte and Interleukin
Yuan Zhijun,Liu Ailin,Liu Lingling. Effect of Buxue Qiangshen Fang Combined with Western Medicine on Chronic Aplastic Anemia and Observation Study on Erythrocyte and Interleukin[J]. World Chinese Medicine, 2018, 0(11)
Authors:Yuan Zhijun  Liu Ailin  Liu Lingling
Affiliation:1 Xiaogan Hospital, Wuhan University of Science and Technology, Xiaogan 432000, China; 2 First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Abstract:To study the self-made Buxue Qiangsheng Fang combined with western medicine in the treatment of chronic aplastic anemia, and the effects on patients'' erythrocyte and interleukin. Methods:A total of 46 cases of chronic aplastic anemia patients in our hospital from June 2014 to December 2015 were selected as the objects of study. All patients were randomly divided into control group and observation group. The control group took western medicine treatment, and the observation group was added self-made Buxue Qiangsheng Fang for treatment. After two courses of treatment, the efficacy of the two groups before and after treatment were evaluated and compared. Red blood cell count, reticulocyte and hemoglobin levels, bone marrow hyperplasia degree, the expression level of serum interleukin factor of two groups were observed before and after treatment. Results:The clinical cure rate of the observation group was 82.61%, and the total effective rate was 95.65%. The clinical cure rate of the control group was 56.52%, and the total effective rate was 78.26%. The clinical curative effect of the observation group was better than that of the control group (P<0.05). After treatment, RBC, RET, Hb of two groups were improved, and the difference was significant when compared within groups (P<0.05). After treatment, RBC, RET, Hb of the observation group were better than the control group (P<0.05). After treatment, the serum IL-17, IL-6, IL-23 were decreased in the two groups, and the difference was significant when compared within groups (P<0.05). After treatment, the IL-17, IL-6, IL-23 in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the observation group was significantly better than the control group (P<0.05). RBC, Hb and clinical efficacy were highly negative correlated (P<0.05), and IL-23, IL-17, IL-6 and clinical efficacy were highly positive correlated (P<0.05). Both were statistically significant. Conclusion:Buxue Qiangsheng Fang combined with western medicine has definite effect in the treatment of chronic aplastic anemia, which can effectively improve the expression level of red blood cells and interleukin factors.
Keywords:Chronic aplastic anemia   Red blood cells   Interleukin-17   Interleukin-6   Interleukin-23   Bone marrow hyperplasia   Hemoglobin   Integrated Chinese and western medicine
本文献已被 CNKI 等数据库收录!
点击此处可从《世界中医药》浏览原始摘要信息
点击此处可从《世界中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号